New drug enters final testing to control devastating liver virus
NCT ID NCT07309380
Summary
This study is testing whether a new drug called Hepalatide (L47) can help control chronic hepatitis D, a serious liver infection. About 150 patients will receive either the drug or a placebo for 48 weeks, while doctors monitor their virus levels and liver health. The goal is to see if the drug can suppress the virus and improve liver function better than a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS D, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Hospital of Jilin University
Changchun, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.